PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
April 15, 2026JAMA Pediatrics0 citations

Out-of-Pocket Cost of Spinal Muscular Atrophy Gene Therapies Among Commercially Insured Patients

View Full Paper
MSMaria SckaffJohns Hopkins UniversityIOIlina C. OdouardJohns Hopkins UniversityJBJeromie BallreichJohns Hopkins University

Key Points

  • To assess the insurance coverage and out-of-pocket costs associated with spinal muscular atrophy gene therapies.
  • Cross-sectional study design
  • Evaluation of commercial insurance data
  • Analysis of patient spending from 2021-2022
  • Overall out-of-pocket costs for patients using SMA therapies were substantial
  • Variations in costs were observed across different therapies
  • Insurance coverage significantly influenced patient expenditure

Abstract

This cross-sectional study evaluates insurance and patient spending for the spinal muscular atrophy medications nusinersen, onasemnogene abeparvovec-xioi, and risdiplam from 2021 through 2022.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Sckaff et al. (2026) studied this question.

synapsesocial.com/papers/69df2cb9e4eeef8a2a6b1ffchttps://doi.org/10.1001/jamapediatrics.2026.0641
Ask AI
Helpful
Bookmark
Share
View Full Paper